NWBO Stock Northwest Biotherapeutics (NWBO, $0.28) entered Uptrend as Momentum indicator ascends above 0 level on May 22, 2025

GET DAILY SIGNALS

Get AI intraday signals

NWBO - Northwest Biotherapeutics, Inc.

Momentum signal

View

Odds of UP Trend

Price: $0.2848

Daily change: +$0.0147 (+5.44%)

Daily volume: 2.2M

Capitalization: $409.5M

Industry: Biotechnology

NWBO in +2.05% Uptrend, advancing for three consecutive days on May 30, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NWBO advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 42 cases where NWBO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on May 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NWBO as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NWBO turned negative on May 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

NWBO moved below its 50-day moving average on June 04, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NWBO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NWBO entered a downward trend on June 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). NWBO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (217.391) is also within normal values, averaging (265.014).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NWBO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NWBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.